Skip to main content
. 2024 Jan 6;23:13. doi: 10.1186/s12933-023-02094-x

Table 2.

Metabolic outcomes

PE E ΔE PI I ΔI ΔT
MR day 1
 Glucose (mmol/L) 8.7 ± 0.5 7.6 ± 0.3 −1.1 ± 0.2** 8.7 ± 0.5 7.6 ± 0.3 −1.1 ± 0.4* −0.0 ± 0.3
 FAs (mmol/L) 0.55 ± 0.03 0.60 ± 0.03 0.05 ± 0.04 0.56 ± 0.04 0.50 ± 0.05 −0.06 ± 0.05 0.10 ± 0.04*
 β-OH butyrate (mmol/L) 0.25 ± 0.02 0.29 ± 0.03 0.05 ± 0.02* 0.26 ± 0.02 0.24 ± 0.02 −0.02 ± 0.01†† 0.05 ± 0.02 *
 Insulin (pmol/L) 127 ± 17 103 ± 14 −24 ± 11 127 ± 17 141 ± 16 14 ± 10† −38 ± 12**
 Respiratory quotient 0.80 ± 0.01 0.75 ± 0.03 −0.04 ± 0.04 0.84 ± 0.02 0.84 ± 0.02 0.00 ± 0.02 −0.09 ± 0.03*
MR day 2—acipimox
 Glucose (mmol/L) 8.7 ± 0.5 7.6 ± 0.3 −1.1 ± 0.4** 8.1 ± 0.3 7.6 ± 0.3 −0.6 ± 0.2* −0.1 ± 0.2
 FAs (mmol/L) 0.33 ± 0.04‡‡ 0.41 ± 0.04‡‡ 0.08 ± 0.05 0.34 ± 0.03‡‡ 0.32 ± 0.04‡‡ −0.02 ± 0.04 0.10 ± 0.05
 Ketone bodies (umol/L) 0.23 ± 0.01 0.25 ± 0.02 0.02 ± 0.01 0.23 ± 0.02‡ 0.22 ± 0.02‡ −0.01 ± 0.02 0.04 ± 0.02*
 Insulin (pmol/L) 139 ± 24 87 ± 9 −52 ± 19* 106 ± 13 149 ± 23 43 ± 14**†† −62 ± 17**

Data are presented as Mean ± SEM

PE Pre-Empagliflozin, E Empagliflozin, PI Pre-Insulin, I Insulin, ΔE E-PE, ΔI I-PI, ΔT E-I

*p < 0.05; **p < 0.01; †p < 0.05; ††p < 0.01 vs ΔE. ‡p < 0.05 vs MR Day 1. ‡‡p < 0.01 vs MR Day 1